We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+31.13%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$4.73B
AUM Growth
+$575M
Cap. Flow
-$186M
Cap. Flow %
-3.94%
Top 10 Hldgs %
46.08%
Holding
127
New
17
Increased
23
Reduced
25
Closed
19

Top Buys

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$95.5M
2
VKTX icon
Viking Therapeutics
VKTX
+$57.4M
3
ARGX icon
argenx
ARGX
+$52.2M
4
ADGM
Adagio Medical Holdings
ADGM
+$46.7M
5
ORKA
Oruka Therapeutics
ORKA
+$43M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$441M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.1M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$60M
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$38.8M
5
SWTX
SpringWorks Therapeutics
SWTX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OMIC
101
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$798K 0.02%
50,896
-20,000
-28% -$178K
KYTX icon
102
Kyverna Therapeutics
KYTX
$547M
$734K 0.02%
150,000
– –
FBRX icon
103
Forte Biosciences
FBRX
$1.63B
$535K 0.01%
95,742
-34,872
-27% -$359K
SYRS
104
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$251K 0.01%
116,754
– –
CMAX
105
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$170K ﹤0.01%
100,000
-22,643
-18% -$69K
RVMDW icon
106
Revolution Medicines Inc Warrant
RVMDW
$132M
$35K ﹤0.01%
250,000
– –
SRZNW
107
DELISTED
Surrozen Inc Warrant
SRZNW
$1.72K ﹤0.01%
166,666
– –
CMAXW
108
DELISTED
CareMax, Inc. Warrant
CMAXW
$594 ﹤0.01%
60,000
– –
AXGN icon
109
Axogen
AXGN
$2.68B
– –
-30,421
Closed -$220K
BBIO icon
110
BridgeBio Pharma
BBIO
$15.7B
– –
-1,215,346
Closed -$30.8M
CABA icon
111
Cabaletta Bio
CABA
$546M
– –
-585,045
Closed -$4.38M
CGEM icon
112
Cullinan Oncology
CGEM
$1.48B
– –
-749,916
Closed -$13.1M
ENGN icon
113
enGene Therapeutics
ENGN
$125M
– –
-800,000
Closed -$7.54M
FHTX icon
114
Foghorn Therapeutics
FHTX
$407M
– –
-544,000
Closed -$3.13M
IMVT icon
115
CALL
Immunovant
IMVT
$8.99B
– –
-200,000
Closed -$5.28M
KALV
116
DELISTED
KalVista Pharmaceuticals
KALV
– –
-500,000
Closed -$5.89M
MDGL icon
117
Madrigal Pharmaceuticals
MDGL
$11.8B
– –
-264,600
Closed -$74.1M
RXRX icon
118
Recursion Pharmaceuticals
RXRX
$1.91B
– –
-769,230
Closed -$5.77M
SPRY icon
119
ARS Pharmaceuticals
SPRY
$569M
– –
-867,319
Closed -$7.38M
TCMD icon
120
Tactile Systems Technology
TCMD
$534M
– –
-62,639
Closed -$748K
XBI icon
121
State Street SPDR S&P Biotech ETF
XBI
$11.8B
– –
-22,665
Closed -$2.23M
SKYE icon
122
Skye Bioscience
SKYE
$8.94M
– –
-62,500
Closed -$4M
TEM
123
Tempus AI
TEM
$12.4B
– –
-275,000
Closed -$9.63M
RVNC
124
DELISTED
Revance Therapeutics, Inc.
RVNC
– –
-600,000
Closed -$1.54M
EGRX
125
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
– –
-173,365
Closed -$971K
2 3 4
5
6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Perceptive Advisors held 127 positions worth $4.73B, up 14% from $4.15B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $186M in Q3 2024, closing 19 positions and reducing 25 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $441M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Perceptive Advisors opened a new position in Adagio Medical Holdings worth $25.3M.

  • Perceptive Advisors's largest Q3 2024 buy was Adagio Medical Holdings: 9,812,419 shares worth $25.3M.
  • Perceptive Advisors added most to Verona Pharma in Q3 2024, an estimated $95.5M increase.
  • Perceptive Advisors's biggest Q3 2024 reduction was Neurocrine Biosciences, cutting an estimated $60M.
  • Perceptive Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $441M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $4.73B portfolio in Q3 2024.
  • Perceptive Advisors opened 17 new positions and closed 19 in Q3 2024.
  • Perceptive Advisors's portfolio value rose 14% quarter-over-quarter to $4.73B.

Based on Perceptive Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.